Compositions and methods for priming monocytic dendritic cells and t cells for th-1response
    3.
    发明申请
    Compositions and methods for priming monocytic dendritic cells and t cells for th-1response 审中-公开
    用于引发单核细胞树突状细胞和t细胞用于th-1反应的组合物和方法

    公开(公告)号:US20050059151A1

    公开(公告)日:2005-03-17

    申请号:US10488744

    申请日:2002-09-06

    申请人: Marnix Bosch

    发明人: Marnix Bosch

    摘要: The present invention provides compositions and methods for inducing maturation of immature dendritic cells (DC) and for priming those cells for inducing a type 1 immune response. The present invention also provides dendritic cell populations useful for activating and for preparing T cells polarized towards production of type 1 cytokines and/or a type 1 response. Similarly, activated, polarized T cell populations, and methods of making the same are provided.

    摘要翻译: 本发明提供用于诱导未成熟树突状细胞(DC)成熟并引发这些细胞诱导1型免疫应答的组合物和方法。 本发明还提供了可用于激活和制备向1型细胞因子产生和/或1型反应产生极化的T细胞的树突状细胞群。 类似地,提供了活化的,极化的T细胞群体及其制备方法。

    Administration of dendritic cells partially matured in vitro for the treatment of tumors
    4.
    发明申请
    Administration of dendritic cells partially matured in vitro for the treatment of tumors 审中-公开
    树突状细胞的施用在体外部分成熟以治疗肿瘤

    公开(公告)号:US20060057120A1

    公开(公告)日:2006-03-16

    申请号:US10538226

    申请日:2003-12-05

    申请人: Marnix Bosch

    发明人: Marnix Bosch

    IPC分类号: A61K35/14 C12N5/08

    摘要: The present invention provides populations of cells comprising partially matured dendritic cells that can be used for administration individuals having a tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 1 to about 10 hours, or more, efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. Once in the lymph node the now fully mature antigen presenting dendritic cells secrete the appropriate cytokines (e.g., TNFα and IL-12) and contact T cells inducing a substantial anti-tumor immune response.

    摘要翻译: 本发明提供包含部分成熟的树突状细胞的细胞群,其可用于给予具有肿瘤的个体。 部分成熟的树突状细胞,与树突状细胞成熟剂接触约1至约10小时或更长时间,有效地占据和处理肿瘤部位的肿瘤抗原,完全成熟,并随后迁移至淋巴结 被治疗的个体。 一旦在淋巴结中,现在完全成熟的抗原呈递树突状细胞分泌适当的细胞因子(例如TNFα和IL-12)并接触诱导大量抗肿瘤免疫应答的T细胞。